Scarica l'app Stockscreener
1.6751
0.87%
-0.0149
Precedente Chiudi:
$1.69
Aprire:
$1.69
Volume 24 ore:
218.43K
Relative Volume:
0.32
Capitalizzazione di mercato:
$106.14M
Reddito:
$139.77M
Utile/perdita netta:
$-97.62M
Rapporto P/E:
-1.0602
EPS:
-1.58
Flusso di cassa netto:
$-61.71M
1 W Prestazione:
-4.81%
1M Prestazione:
+5.36%
6M Prestazione:
+29.87%
1 anno Prestazione:
-59.53%
Intervallo 1D:
$1.635
$1.71
Intervallo di 1 settimana:
$1.635
$1.83
Portata 52W:
$0.9897
$5.10
Macrogenics Inc Stock (MGNX) Company Profile
Nome
Macrogenics Inc
Settore
Industria
Telefono
301-251-5172
Indirizzo
9704 MEDICAL CENTER DRIVE, Rockville, MD
Confronta MGNX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
1.6792 | 106.82M | 139.77M | -97.62M | -61.71M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.62 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.68 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
552.20 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
809.14 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.45 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-17 | Ripresa | Barclays | Overweight |
| 2024-11-07 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-08-01 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-07-31 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2024-07-31 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-05-10 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-05-10 | Downgrade | Stifel | Buy → Hold |
| 2024-05-10 | Downgrade | TD Cowen | Buy → Hold |
| 2024-04-26 | Iniziato | B. Riley Securities | Buy |
| 2024-04-09 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-03-04 | Reiterato | BTIG Research | Buy |
| 2024-02-14 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-12-20 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-17 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-11-22 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-11-14 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-07-18 | Downgrade | SMBC Nikko | Outperform → Neutral |
| 2022-07-11 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-05-04 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-02-28 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-02-11 | Iniziato | BMO Capital Markets | Outperform |
| 2022-02-04 | Iniziato | SMBC Nikko | Outperform |
| 2021-11-17 | Ripresa | Guggenheim | Buy |
| 2021-10-19 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-12 | Aggiornamento | Barclays | Underweight → Overweight |
| 2020-12-22 | Ripresa | H.C. Wainwright | Buy |
| 2020-08-03 | Downgrade | Citigroup | Buy → Neutral |
| 2020-06-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-05-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-04 | Iniziato | Barclays | Underweight |
| 2019-12-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-12-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-11-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-11-20 | Ripresa | Guggenheim | Neutral |
| 2019-05-03 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2019-04-12 | Iniziato | Guggenheim | Neutral |
| 2019-02-07 | Aggiornamento | Citigroup | Sell → Buy |
| 2019-02-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-02-06 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2019-02-04 | Downgrade | Citigroup | Neutral → Sell |
| 2018-12-10 | Downgrade | Raymond James | Outperform → Underperform |
| 2018-09-10 | Ripresa | BTIG Research | Buy |
| 2018-05-31 | Iniziato | Evercore ISI | Outperform |
| 2018-03-05 | Iniziato | H.C. Wainwright | Buy |
| 2017-03-31 | Iniziato | Raymond James | Outperform |
Mostra tutto
Macrogenics Inc Borsa (MGNX) Ultime notizie
Chart based analysis of MacroGenics Inc. trends2025 Volume Leaders & Expert Curated Trade Ideas - newser.com
Will MacroGenics Inc. stock rally after Fed decisions2025 Short Interest & Consistent Profit Alerts - newser.com
Can MacroGenics Inc. stock hit record highs againEarnings Overview Report & Long-Term Growth Portfolio Plans - newser.com
When is the best time to exit MacroGenics Inc.July 2025 Momentum & Low Risk High Reward Trade Ideas - newser.com
Applying Wyckoff theory to MacroGenics Inc. stock2025 Investor Takeaways & Daily Entry Point Trade Alerts - newser.com
Weiss Ratings Reaffirms Sell (E+) Rating for MacroGenics (NASDAQ:MGNX) - MarketBeat
Bispecific Antibodies MarketGlobal Forecast 2025-2032, Profiles of Key PlayersF. Hoffmann-La Roche, Amgen, Janssen Biotech, Pfizer, AbbVie, Regeneron, MacroGenics, AstraZeneca, Merck, and Genmab - Yahoo
Public Employees Retirement System of Ohio Has $31,000 Stake in MacroGenics, Inc. $MGNX - Defense World
MacroGenics, Inc. (NASDAQ:MGNX) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
MacroGenics (NASDAQ:MGNX) and CeriBell (NASDAQ:CBLL) Head to Head Comparison - Defense World
Regression analysis insights on MacroGenics Inc. performanceDay Trade & Weekly Market Pulse Updates - newser.com
Using data models to predict MacroGenics Inc. stock movementJuly 2025 Spike Watch & Low Risk Profit Maximizing Plans - newser.com
Published on: 2025-10-05 06:01:39 - newser.com
Backtesting results for MacroGenics Inc. trading strategies2025 EndofYear Setup & Daily Risk Controlled Trade Plans - newser.com
Multi asset correlation models including MacroGenics Inc.Quarterly Profit Review & Weekly Breakout Stock Alerts - newser.com
How currency fluctuations impact MacroGenics Inc. stockJuly 2025 Breakouts & Expert Approved Momentum Trade Ideas - newser.com
Developing predictive dashboards with MacroGenics Inc. dataWeekly Investment Report & Verified Entry Point Signals - newser.com
Published on: 2025-10-02 22:14:22 - newser.com
Voya Investment Management LLC Buys 40,500 Shares of MacroGenics, Inc. $MGNX - Defense World
Published on: 2025-09-30 05:12:41 - newser.com
What drives MacroGenics Inc stock priceCash Flow Trends & Amplify Gains With Picks - earlytimes.in
Goldman Sachs Group Inc. Has $251,000 Position in MacroGenics, Inc. $MGNX - MarketBeat
Extensive-Stage Small Cell Lung Cancer Pipeline 2025: Innovative Clinical Developments By 25+ Global Leaders Delveinsight Key Companies Featured Include Shanghai Henlius Biotech, Macrogenics, Inc. - Menafn.com
What drives PROG Holdings Inc AZD stock priceInterest Rate Changes & Small Capital Wealth Plans - earlytimes.in
*DJ Macrogenics Announces Removal of Partial Clinical Hold on MGD009 Program by FDA >MGNX - 富途牛牛
Strs Ohio Invests $263,000 in MacroGenics, Inc. $MGNX - MarketBeat
Intraday pattern recognizer results for MacroGenics Inc.July 2025 PostEarnings & Real-Time Volume Analysis - newser.com
Statistical indicators supporting MacroGenics Inc.’s strengthIPO Watch & Accurate Entry and Exit Point Alerts - newser.com
Published on: 2025-09-22 05:42:18 - newser.com
Barclays Upgrades MacroGenics (NASDAQ:MGNX) to "Strong-Buy" - MarketBeat
MacroGenics (NASDAQ:MGNX) Now Covered by Analysts at Barclays - MarketBeat
Acadian Asset Management LLC Grows Position in MacroGenics, Inc. $MGNX - MarketBeat
Live market analysis of MacroGenics Inc.Quarterly Market Summary & Safe Capital Allocation Plans - newser.com
What institutional flow reveals about MacroGenics Inc.July 2025 Drop Watch & Capital Efficient Trade Techniques - newser.com
Momentum divergence signals in MacroGenics Inc. chartProfit Target & Weekly Market Pulse Alerts - newser.com
What indicators show strength in MacroGenics Inc.Weekly Investment Report & Free Growth Oriented Trading Recommendations - newser.com
Using economic indicators to assess MacroGenics Inc. potential2025 Trading Volume Trends & Safe Entry Zone Identification - newser.com
MacroGenics Inc. stock trend outlook and recovery pathDay Trade & Daily Technical Stock Forecast Reports - newser.com
Growth Recap: Will MacroGenics Inc outperform the market in YEARJuly 2025 Sentiment & Fast Entry High Yield Tips - خودرو بانک
Macrogenics Inc Azioni (MGNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Macrogenics Inc Azioni (MGNX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| HEIDEN WILLIAM K | Director |
Aug 20 '25 |
Buy |
1.49 |
49,500 |
73,755 |
111,000 |
| Koenig Scott | Director |
Aug 13 '25 |
Option Exercise |
0.00 |
52,829 |
0 |
830,244 |
| Bonvini Ezio | Sr VP, Research & CSO |
Feb 15 '25 |
Option Exercise |
0.00 |
16,665 |
0 |
124,414 |
| Karrels James | SVP, CFO and Secretary |
Feb 15 '25 |
Option Exercise |
0.00 |
14,998 |
0 |
192,591 |
| Koenig Scott | President and CEO |
Feb 15 '25 |
Option Exercise |
0.00 |
42,329 |
0 |
777,415 |
| Peters Jeffrey Stuart | Senior VP and General Counsel |
Feb 15 '25 |
Option Exercise |
0.00 |
13,332 |
0 |
18,858 |
| Risser Eric Blasius | Chief Operating Officer |
Feb 15 '25 |
Option Exercise |
0.00 |
16,665 |
0 |
62,422 |
| Smith Beth Ann | VP, Controller & Treasurer |
Feb 15 '25 |
Option Exercise |
0.00 |
1,095 |
0 |
9,955 |
| Smith Beth Ann | VP, Controller & Treasurer |
Feb 15 '25 |
Sale |
2.56 |
423 |
1,083 |
9,532 |
| Spitznagel Thomas | Sr VP, Technical Ops |
Feb 15 '25 |
Option Exercise |
0.00 |
13,332 |
0 |
26,922 |
1.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):